glp-1 patent Landscape: Who Leads the Innovation Race Pharma or Food? Competing in the Post-Patent GLP-1

Healthcare providers use BMI as a screening tool to identify whether someone may be underweight, at a healthy weight, overweight, or living with obesity

Additional benefits observed: Substantial reduction in knee osteoarthritis pain (75.8% reduction in pain scores) Improved cardiovascular risk markers (non-HDL cholesterol, triglycerides, blood pressure) Up to 86% of participants with fatty liver disease achieved normal liver fat levels Early research suggests retatrutide may lead to substantial weight loss in clinical trial settings, but long-term safety, tolerability, and real-world outcomes still need more data

There's an interesting wrinkle for people with diabetes

It provides valuable insights into how these medications interact with the body's hormonal systems, emphasizing their role beyond weight loss